Unicycive Therapeutics, Inc. (UNCY)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.0M | -7.3M | -7.2M | -8.4M |
| Net Income | -6.4M | -6.0M | -14.7M | -12.8M |
| Diluted EPS | $-0.52 | $-0.33 | $nan | $-0.54 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 951K | 675K | 0.00 | 0.00 |
| Operating Income | -18.1M | -20.8M | -32.1M | -29.5M |
| Net Income | -18.1M | -30.5M | -36.7M | -26.6M |
| Diluted EPS | $-12.00 | $-12.80 | $-5.65 | $-1.67 |